An interventional study of Neuclare in Dementia, Mild and Cognitive Disorder Mild, sponsored by Deepsonbio. Status unknown at 2 sites in Korea, Republic of. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-03-24.
Sponsored by Deepsonbio · Not applicable, Interventional, and Treatment
This clinical trial aims to explore the effectiveness and safety of cognitive function improvement of Neuclare, a science medical device, for patients with mild cognitive impairment and early Alzheimer's disease.
Through methods such as Trail Making Test Black \& White, Attention Questionnaire Scale(AQS), Neuropsychiatric Inventory (NPI), etc, cognitive function improvement before and after using Neuclare will be evaluated.
2,172 studies on the registry are indexed under Dementia; 540 are open to participants now.
This study's planned enrollment of 20 is below the median of 83 across 1,629 interventional studies indexed under Dementia.
Browse Dementia studies →Deepsonbio is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The patient with mild cognitive disorder and early dementia who will be treated with the medical device-Neuclare
Device: Neuclare
It is used to stimulate the brain for a certain period of time to improve cognitive impairment in patients with cognitive disorder. In this clinical trial, it is used for patients with mild cognitive disorder and demincia symptoms.
Change of Trail Making Test Black & White Score : From Baseline to Week 5
Compare with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as evaluated by Trail Making Test Black \& White Score
Time frame: Week 5
Change of Attention Questionnaire Scale : From Baseline to Week 5
Compare with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as evaluated by Attention Questionnaire Scale
Time frame: Week 5
Change of Neuropsychiatric Inventory Score : From Baseline to Week 5
Compare with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as evaluated by Neuropsychiatric Inventory score
Time frame: Week 5
Change of Quality of life-AD Score : From Baseline to Week 5
Compare with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as evaluated by Quality of life-AD Score
Time frame: Week 5
Change of MMSE-II Score : From Baseline to Week 5
Compare with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as evaluated by MMSE-II Score
Time frame: Week 5
change of beta-amyloid deposition measured by Amyloid PET-CT : From Baseline to Week 5
change of beta-amyloid deposition with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as measured by Amyloid PET-CT
Time frame: Week 5
Change of glucose metabolic rate in brain measured by FDG PET-CT : From Baseline to Week 5
Compare glucose metabolic rate with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as measured by FDG PET-CT
Time frame: Week 5
Change of Aβ oligomer density measured by MDS-OAβ test result : From Baseline to Week 5
Compare Aβ oligomer density with before and after using Neuclare for the treatment of mild cognitive disorder and early dementia as measured by MDS-OAβ test
Time frame: Week 5
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Deepsonbio